Management of hypercholesterolaemia in the patient with diabetes

International Journal of Clinical Practice, Supplement

Volumn , Issue 130, 2002, Pages 27-32

  Packard, C ^a   Olsson, A G ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY RISK; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPOPROTEINS, VLDL; NIACIN; RISK FACTORS; TRIGLYCERIDES;

EID: 0036633356     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Diabetic dyslipidemia
2. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
4. Hyperglycemia and cardiovascular disease in type 2 diabetes
5. Management of coronary artery disease: Therapeutic options in patients with diabetes
6. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease
7. Diabetes, statins, fibrates, or both?
8. Type 2 diabetes: Epidemiology, pathophysiology, and diagnosis
9. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus
10. Position statement. Management of dyslipidemia in adults with diabetes
11. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease
12. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
13. Risk factors for cardiovascular disease in individuals with diabetes. The Strong Heart Study
14. HDL and arteriosclerosis: Beyond reverse cholesterol transport
15. Prevalence of coronary risk factors in non-insulin dependent (type 2) diabetes
16. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
17. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study
18. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) Trial
19. Effect of pravastatin on coronary events in subgroups defined by coronary risk factors
20. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
21. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
22. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
23. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
24. Diabetic dyslipidemia. Current treatment recommendations
25. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease. The Benzafibrate Infarction Prevention (BIP) Study
26. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia
27. Learning from the cerivastatin experience
28. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study
29. Comparison of statins in hypertriglyceridemia
30. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia
31. Fluvastatin with and without niacin for hypercholesterolemia
32. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
33. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia
34. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
35. Rosuvastatin alone and in combination with fenofibrate for hyperlipidaemic patients with type 2 diabetes
36. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia